Nasdaq:HALO
HALOZYME THERAPEUTICS, INC.
A biopharmaceutical innovator utilizing the HaloZyme platform to deliver advanced therapeutic proteins with strong recent revenue growth and profitability.
Key Metrics
Investment Thesis
Bull Case
Investors should consider HALOZYME for its unique HaloZyme technology platform which offers a competitive edge in the high-value biopharmaceutical market. The company has demonstrated strong profitability with gross profits reaching $1.17B against revenue of $1.40B, suggesting excellent operational leverage. Strategic acquisitions have expanded the product pipeline, positioning the firm for potential future growth as new therapies reach commercial maturity.
Bear Case
The stock carries elevated risk due to a debt load of $2.14B which significantly outweighs shareholders' equity of $48.8M, limiting financial flexibility. Recent earnings volatility with net income falling from $444.1M in 2024 to $316.9M raises concerns about the sustainability of current profit levels. Significant investing cash outflows of -$545.8M and other investing activities of -$1.53B indicate heavy capital consumption that may strain liquidity if future revenue growth stalls.
About HALOZYME THERAPEUTICS, INC.
HALOZYME Therapeutics is a biopharmaceutical company focused on developing novel therapies, primarily leveraging its proprietary HaloZyme technology platform to create advanced therapeutic proteins. The company serves the global pharmaceutical and medical markets with a portfolio designed to address unmet needs in oncology and other serious diseases. Financially, the firm reports significant gross margins driven by high-margin product sales alongside substantial investments in long-term assets and goodwill from strategic acquisitions.
Analysis
Management Discussion
HALOZYME reported strong operational performance with net profit of $316.9M, though this represents a decline from the prior year's $444.1M peak, indicating some volatility in earnings trajectory. The company maintained a healthy cash position with ending cash of $136.4M and generated substantial operating cash flow of $651.6M, offsetting significant investing outflows related to acquisitions totaling $726.0M. Despite high total liabilities of $2.48B, the firm's current assets of $825.2M provide a working capital buffer that supports ongoing operational needs.
Industry Overview
The biopharmaceutical industry is characterized by high barriers to entry, intense competition for patent exclusivity, and rapid technological advancement in protein engineering and drug delivery systems. Companies in this sector face rigorous regulatory oversight requiring extensive clinical trials before product approval, leading to long development cycles and substantial R&D expenditures. Market dynamics favor firms with proprietary platforms that can differentiate their products from established competitors while navigating pricing pressures from healthcare payers.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $660.1M | $829.3M | $1.02B | $1.40B |
| Cost of Revenue | $139.3M | $192.4M | $159.4M | $228.8M |
| Gross Profit | $520.8M | $636.9M | $855.9M | $1.17B |
| Operating Expenses | $253.3M | $299.3M | $304.4M | $698.8M |
| Operating Income | $267.5M | $337.6M | $551.5M | $469.0M |
| R&D | $66.6M | $76.4M | $79.0M | — |
| G&A | $143.5M | $149.2M | $154.3M | $207.1M |
| Stock-Based Comp | $24.4M | $36.6M | $43.4M | $51.6M |
| D&A | $6.5M | $11.1M | $10.3M | $11.4M |
| Amortization | $43.1M | $73.8M | $71.0M | $76.7M |
| Other OpEx | $43.1M | $73.8M | $71.0M | $491.7M |
| Non-Operating Income | $-18.6M | $10.8M | $5.7M | $-2.1M |
| Interest Expense | $16.9M | $18.8M | — | — |
| Pre-Tax Income | $248.9M | $348.3M | $557.1M | $466.9M |
| Income Tax | $46.8M | $66.7M | $113.0M | $150.0M |
| Continuing Ops | $202.1M | $281.6M | $444.1M | $316.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $202.1M | $281.6M | $444.1M | $316.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $202.1M | $281.6M | $444.1M | $316.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $739.0M | $746.4M | $1.09B | $825.2M |
| Cash & Equivalents | $234.2M | $118.4M | $115.8M | $133.8M |
| Accounts Receivable | $231.1M | — | $288.2M | $426.3M |
| Inventory | $100.1M | $127.6M | $141.9M | $176.5M |
| Prepaid Expenses | $45.0M | $48.6M | $39.0M | $64.6M |
| Other Current Assets | $128.6M | $451.8M | $500.5M | $24.0M |
| Long-Term Assets | $1.10B | $986.8M | $978.1M | $1.70B |
| PP&E (Net) | $35.1M | $38.1M | $40.9M | $44.4M |
| Intangibles | $546.7M | $472.9M | $401.8M | $981.5M |
| Goodwill | $409.0M | $416.8M | $416.8M | $580.4M |
| Operating Leases | $40.5M | $36.8M | $34.2M | $37.7M |
| Other LT Assets | $71.2M | $22.2M | $84.5M | $56.2M |
| Total Assets | $1.84B | $1.73B | $2.06B | $2.53B |
| Current Liabilities | $130.8M | $112.5M | $139.1M | $177.1M |
| Accounts Payable | $17.7M | $11.8M | $10.2M | $20.9M |
| Current Debt | $13.3M | $0 | $0 | $0 |
| Deferred Revenue | $3.2M | — | — | — |
| Other Current Liab | $0 | $0 | $0 | $0 |
| Long-Term Liabilities | $1.54B | $1.54B | $1.56B | $2.30B |
| Long-Term Debt | $1.49B | $1.50B | $1.51B | $2.14B |
| Other LT Liab | $45.9M | $37.7M | $54.8M | $156.8M |
| Total Liabilities | $1.67B | $1.65B | $1.70B | $2.48B |
| Shareholders' Equity | $169.8M | $83.8M | $363.8M | $48.8M |
| Retained Earnings | $143.2M | $90.5M | $359.9M | $54.8M |
| AOCI | $-922.0K | $-9.3M | $3.8M | $-18.1M |
| Total L&E | $1.84B | $1.73B | $2.06B | $2.53B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $202.1M | $281.6M | $444.1M | $316.9M |
| Non-Cash Adjustments | $-57.0M | $127.9M | $-147.8M | $170.6M |
| Working Capital Changes | $95.0M | $-20.9M | $182.7M | $164.0M |
| Cash from Operations | $240.1M | $388.6M | $479.1M | $651.6M |
| Capital Expenditures | $4.8M | $15.3M | $10.7M | $7.0M |
| Cash from Investing | $-487.0M | $-96.9M | $-262.7M | $-545.8M |
| Share Buybacks | $200.0M | $402.4M | $250.0M | $342.4M |
| Cash from Financing | $362.4M | $-408.0M | $-218.9M | $-85.2M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $115.5M | $-116.3M | $-2.5M | $20.6M |
| Beginning Cash | $119.2M | $234.7M | $118.4M | $115.8M |
| Ending Cash | $234.7M | $118.4M | $115.8M | $136.4M |
Frequently Asked Questions
How does HALOZYME THERAPEUTICS, INC. make money?
Primary revenue streams include commercialization of proprietary HaloZyme-derived products, licensing agreements for its unique technology platform, and potential collaboration revenues from strategic partnerships in oncology and other therapeutic areas.
What are the main risks for HALO?
The company faces significant debt exposure with long-term debt of $2.14B relative to shareholders' equity of only $48.8M, creating leverage risk during economic downturns. Dependence on continued revenue growth is critical as net income dropped from a 2024 peak of $444.1M to $316.9M in the most recent year. Strategic risks include potential regulatory delays in drug approvals and the high cost of maintaining R&D programs without corresponding new product launches.
What is HALO's competitive advantage?
The company possesses a differentiated technology platform that enables the creation of novel therapeutic proteins with enhanced stability and efficacy. Its robust intellectual property portfolio surrounding the HaloZyme platform provides strong patent protection against generic competition. The firm has demonstrated operational efficiency, converting operations cash flow to net income at a ratio exceeding 200% in the latest period.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.